{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-028027","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.971611+00:00","generated_at":"2026-06-24T04:22:31.492456+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sana Q2 net loss $72.5M; cash runway extended into 2025 on manufacturing move savings","bullets":["Cash position $579.6M at June 30, 2022, down $167.3M from Dec 31, 2021.","Q2 net loss $72.5M ($0.39 per share) vs net income $18.7M in Q2 2021.","Expect cash runway into 2025; ~$100M cost savings from relocating manufacturing to Bothell, WA.","Plan to file INDs in 2022 for SC291 and SG295; SC451 (type 1 diabetes) IND in 2023.","Presented preclinical data showing survival of HIP pancreatic islet cells, cardiomyocytes, RPE cells in NHP."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-028027","json":"https://secwatch.observer/filing/0001564590-22-028027.json","markdown":"https://secwatch.observer/filing/0001564590-22-028027.md","text":"https://secwatch.observer/filing/0001564590-22-028027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000156459022028027/0001564590-22-028027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000156459022028027/sana-8k_20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:22:31.492456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}